FTC Backs J&J's FTC Synthes Acquisition in Light of Conditional Biomet Deal

, The Am Law Daily


In a move that removes an obstacle to its proposed $21.3 billion acquisition of Synthes, Johnson & Johnson has agreed to sell its global trauma business to Biomet Inc. for $280 million. Weil is serving as antitrust counsel to J&J, while Cravath is serving as deal counsel on both transactions. Cleary is advising Biomet.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisAdvance® Here

Not a LexisAdvance® Subscriber?

Subscribe Now

Why am I seeing this?

LexisAdvance® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisAdvance® customers will be able to access and use ALM's content by subscribing to the LexisAdvance® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Legaltech News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisAdvance® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202559187848

Thank you!

This article's comments will be reviewed.